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Abstract
Executioner caspase-3 and -7 are proteases promoting cell death but non-apoptotic roles
are being discovered. The heart expresses caspases only during development, suggesting
they contribute to the organ maturation process. Therefore, we aimed at identifying novel
functions of caspases in heart development. We induced simultaneous deletion of execu-
tioner caspase-3 and -7 in the mouse myocardium and studied its effects. Caspase knock-
out hearts are hypoplastic at birth, reaching normal weight progressively through myocyte
hypertrophy. To identify the molecular pathways involved in these effects, we used microar-
ray-based transcriptomics and multiplexed quantitative proteomics to compare wild type
and executioner caspase-deficient myocardium at different developmental stages. Tran-
scriptomics showed reduced expression of genes promoting DNA replication and cell
cycle progression in the neonatal caspase-deficient heart suggesting reduced myocyte
proliferation, and expression of non-cardiac isoforms of structural proteins in the adult null
myocardium. Proteomics showed reduced abundance of proteins involved in oxidative
phosphorylation accompanied by increased abundance of glycolytic enzymes underscoring
retarded metabolic maturation of the caspase-null myocardium. Correlation between mRNA
expression and protein abundance of relevant genes was confirmed, but transcriptomics
and proteomics indentified complementary molecular pathways influenced by caspases in
the developing heart. Forced expression of wild type or proteolytically inactive caspases in
cultured cardiomyocytes induced expression of genes promoting cell division. The results
reveal that executioner caspases can modulate heart’s cellularity and maturation during
development, contributing novel information about caspase biology and heart development.
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Introduction
Caspases constitute a family of Cysteine-dependent Aspartate-directed proteases participating
in apoptotic cell death [1]. By cleaving their targets, which include caspases themselves, cas-
pases regulate many aspects from death signal propagation within the cell to genomic DNA
degradation. Caspase gene mutation and deletion experiments unveiled their direct and evolu-
tionally conserved implication in the control of embryonic cell death [2–4]. Interestingly, in
vivo deletion of initiator caspase-8, which triggers the cell death intracellular signaling upon
death receptor activation, or deletion of its regulators Cellular FADD-like IL-1β-converting
enzyme-inhibitory protein (cFLIP) and FADD, lead to alterations in cardiac muscle differentia-
tion [5–7]. Executioner caspase-3 and -7 function normally downstream of initiator caspases
and their global deletion also impair cardiac muscle differentiation [8]. In addition, the effects
of in vitro embryo culture in presence of caspase inhibitors suggested a role of caspase proteo-
lytic activity in heart formation and muscle differentiation [9, 10].
Ubiquitous deletion of caspases prevented from identifying whether cardiac defects resulted
from missing caspase activity in the developing myocardium or were secondary to defects in
other tissues or cell types [11, 12]. Therefore, a conditional mouse knock out model is required
to determine the role of caspases in the myocardium. Furthermore, the molecular and bio-
chemical changes occurring in the heart underlying the morphological changes due to deletion
of caspases or their regulators [5–7] has never been analyzed before.
To investigate the role of executioner caspases in cardiomyocytes in vivo we generated and
studied cardiomyocyte-specific caspase-3 null / caspase-7 null mice in a C57BL/6J genotype.
We demonstrate that caspase-3 and -7 influence cardiomyocyte number and proteome. Execu-
tioner caspase deficient hearts have broad changes in gene expression including decreased
expression of genes involved in cell cycle progression. Quantitative proteomics suggested meta-
bolic retardation occurring in the caspase-deficient heart and in vitro experiments confirmed
the influence of caspases in the regulation of genes involved in cell division. Our results also
show that caspase proteolytic activity is not required for regulating gene expression. Our find-
ings complement previous knowledge on the functions of caspases in cardiac development and
expand the understanding of executioner caspase activity.
Materials and Methods
Animal experimentation and ethics statement
The investigation with experimental animals was approved by the Experimental Animal Ethic
Committee of the University of Lleida (codes CEEA06-01/10,07-01/10, 08-01/09 and 09-01/
09) and conforms to the Guide for the Care and Use of Laboratory Animals, 8th Edition, pub-
lished in 2011 by the US National Institutes of Health. All mice (Mus musculus) had a C57BL/
6J background and were housed at the Specific Pathogen Free facility of the Experimental Ani-
mal Platform—Parc Científic de Barcelona, lights on from 7 a.m. to 7 p.m., temperature = 18-
22°C and 30–70% humidity. Animals are housed in Tecniplast GM500 cages (391x199x160
mm) never exceeding 5 adults / cage. Enriched environment includes autoclaved cellulose
material. Animals are feeded 2914 diet (Irradiated Teklad Global 14% Protein Rodent Mainte-
nance Diet, Harlan) and sterilized tap water, both ad libitum. Wellbeing of animals is moni-
tored daily by visual inspection and each eight weeks pathogen analysis is monitored from
sentinel animals following the standards determined by the Federation of European Laboratory
Animal Science Association (FELASA). See ARRIVAL Guidelines Checklist (S1 File). Full cas-
pase-7-deficient cardiac-specific caspase-3-deficient mouse strain was generated by crossing of
caspase-7-deficient [8] and caspase-3 floxed mice [13] with the Nkx2.5::Cre transgenic mouse
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strain, a kind gift of Dr. Eric N. Olson (UT Southwestern Medical Center, Dallas, TX, USA)
[14] (Figure A in S3 File). Genotypes were analyzed by PCR using tail DNA as a template,
primer sequences can be found in S2 File and Figure B in S3 File. For each experiment requir-
ing animals, they were randomly taken by the Facility staff from available individuals of the
required age, gender and genotype. Animals were anesthetized with a lethal dose of inhaled iso-
fluorane and decapitated within the Facility by expert staff. For protein and RNA extraction,
hearts were dissected minced into small cubes, rinsed with cold phosphate buffered saline and
snap-frozen into liquid nitrogen. For hypertrophy experiments, six 20-week-old mice per geno-
type were anesthetized with inhaled isofluorane (4% for induction and 2% for maintenance)
for subcutaneous implantation of mini-osmotic pumps (Alzet, Durect Corporation) loaded
with isoproterenol (Sigma-Aldrich), 8.8mg/kg/day, or saline vehicle, which were administered
for one week [15]. Cardiac hypertrophy was evaluated by measuring heart weight vs. tibia
length of sacrificed mice at the end of the treatment.
Cell cultures
Rat neonatal cardiomyocytes were obtained from the ventricles of 1 to 4-day-old Sprague-
Dawley pups housed in the conventional Animal Facility of the University of Lleida, as
described previously [16]. Human Embryonic Kidney 293 cells (HEK293) were cultured and
used both as positive control for cell death counting and for virus production as reported previ-
ously [17]. Staurosporine (Sigma-Aldrich) was added to the culture medium at 1µM and main-
tained for 16 hours before cell processing. Cell death was quantified using the Trypan Blue
exclusion assay [18]. The number of independent experiments and intra-experiment replicas is
specified in each figure legend.
Transthoracic echocardiography
Echocardiographic measurements were performed using a Vivid portable ultrasound system
with a ILS 12 MHz transducer (GE Healthcare) as described earlier [19]. Ejection fraction (EF),
end-diastolic left ventricular internal diameter (LVEDD), end-systolic left ventricular internal
diameter (LVESD), interventricular septum thickness (IVS) and posterior wall thickness
(LVPW) were measured in M-mode recordings. Fractional shortening (FS) was calculated as
([LVEDD− LVESD]/LVEDD)×100. Nine adult wild type mice and 10 caspase-3 and -7 double
knockout mice were used.
Histological analysis of cell size in mouse hearts
Staining of heart sections with FITC-conjugated wheat germ agglutinin (WGA) was carried
out as previously described [20]. In brief, animal’s codes were registered and mice were sacri-
ficed by qualified technical personnel at the Animal Care Facility, hearts were fixed, included
in paraffin blocks and 3 µm-thick slices were produced, stained with WGA-FITC and
mounted. Slices obtained at two levels separated by 250–300 µm were stained for each heart to
assure the presence of different myocytes. Each coverslip was identified with an Id code associ-
ated to the animal. Fluorescent microscopy images from 2 separate fields each covering 300
cells from each one of 6 animals per genotype, gender and age were obtained by a pathologist,
who identified images with an Id code. The cross-sectional area of all cells appearing in full in
the images was recorded using ImageJ software. Mean cross-sectional area was calculated for
each heart and then the values were paired to the mouse of origin using the Id code and pooled
per anatomical region (septum, ventricle), gender, age and genotype and the respective means
were calculated.
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Quantification of cardiomyocyte cell number
Cardiomyocytes from wild type and caspase-3,7 double knockout hearts were isolated using
the method described previously [21, 22]. Briefly, hearts were dissected and formol-fixed at
4°C followed by a treatment with 12.5M KOH overnight at 4°C. After a 10min vortex to disso-
ciate the cells, cells were passed through a 250μmmesh, centrifuged, suspended in phosphate
buffered saline (PBS) and cardiomyocytes were counted using a Neubauer chamber. Cardio-
myocytes in the counting chamber were distinguished from fibroblasts and debris by cyto-
plasmic size and cell shape. The total number of cardiomyocytes from wild-type neonatal
hearts was in the range of 106, in accordance to reported values [22]. Six hearts per gender, age
and genotype were processed and counted as explained in the figure legend.
Preparation of subcellular extracts
Subcellular fractionation of rat neonatal cardiomyocytes was performed to analyze the localiza-
tion of caspase-3 and caspase-7. Cytosolic fraction was performed as previously reported [16].
Mitochondrial fraction was obtained with the Mitochondria Isolation kit for cultured cells
(Thermo Scientific) and nuclear fraction was obtained with the Nuclei EZ Prep Nuclei Isola-
tion kit (Sigma-Aldrich), in both cases we followed the protocol determined by the supplier.
Subcellular extract’s purity was checked by Western Blot using validated fraction markers as
described in the figure legend.
Lentiviral driven protein overexpression
Open reading frames (ORF) of human Caspase-3 and Caspase-7 (Source Bioscience) were
amplified with primers adding EcoRI and XhoI sequences to 5’ and 3’ ends respectively,
digested (Takara), purified (Nucleospin Extract II, Magerey-Nagel), subcloned into pcRII
(Invitrogen) by using T4 DNAligase (Takara) and amplified in E. coli Stbl2 (Invitrogen). Then,
a SfiI fragment containing the ORF was subcloned in the pEIGW-SK lentiviral vector (kind gift
of Dr. Trono, Switzerland). Cysteine to Serine mutants from Caspase-3 and Caspase-7 were
obtained using a Site-Directed Mutagenesis System (LifeTechnologies), and their ORF were
sequence-verified. Lentiviruses were prepared in the HEK293T packing cell line as described
previously [17]; cardiomyocytes were treated or processed after 4 days of transduction, as
described elsewhere [17].
RNA extraction, microarrays, reverse transcription and quantitative PCR
For heart and cardiomyocytes, total RNA was obtained from frozen tissues or cell pellets with
the RNeasy Mini Kit (Qiagen). RNA concentration measurements and reverse transcription
were done as described [17, 23]. For microarrays, RNA was extracted from either six wild-type
(three males and three females) or double knockout hearts at P0-1 and at P30-35, totaling 24
samples. All heart RNA was from ventricle tissue only and passed several quality controls as
scheduled by the facility. Detailed description of the procedures can be found in S2 File. Quan-
titative Real Time PCR was performed in a iCycler iQ PCR detection system and iQ v.3 and iQ
v.5 software (BioRad), using the Taq Man Gene Expression Master Mix (Cat.N. 4369016) and
the Gene Expression Assays from Applied Biosystems to amplify the transcripts of mouse cdc6
(cell division cycle-6), cenpa, fam107a,myh11 (Myosin heavy Chain 11), nppa (Natriuretic
peptide precursor) and slc2a4; mouse and rat ccne1 (Cyclin E1), ndrg4, pold1 (DNA polymerase
subunit delta) andmef2a; and rat serpina3, with simultaneous amplification of gapdh as load-
ing control (Applied Biosystems). In each qPCR assay, a mean threshold cycle (Ct) was
obtained from triplicates of two or three independent samples. The sample Ct was corrected
Characterization of the Executioner Caspase-Deficient Mouse Heart
PLOS ONE | DOI:10.1371/journal.pone.0131411 June 29, 2015 4 / 21
using the Ct of the loading control (gapdh) to obtain the ΔCt value. Then, differences for each
sample against a reference sample (e.g. neonatal values) were calculated as a final ΔCt = ΔCtre-
ference- ΔCtsample. Relative transcript abundance was then calculated using final ΔCt as 2
ΔCt. The
number of independent samples and replicates is specified in the figure legends.
Protein extraction, SDS-PAGE andWestern Blot
Protein expression was analyzed in 40 μg of total protein extracts from cell cultures and tissues
diluted in Tris-buffered 2% SDS solution at pH 6.8 and SDS-PAGE was performed as described
[17]. Antibody specifications are described in S2 File. Western blots were performed as
reported [17]. Densitometric quantification of the bands was performed with the ImageJ soft-
ware from scanner images of film exposures in which bands were not saturated. Values were
expressed as arbitrary units (AU) corresponding to the signal numerical value given by ImageJ.
Densitometric values of the proteins of interest were not corrected by the loading control
(GAPDH) given the high signal/expression of this enzyme compared with proteins regulating
DNA biology and cell cycle. Procedures were conducted with extreme accuracy to assure equal
inter- and intra-experiment loading for each sample, which was assessed by Coomassie stain-
ing of the gel. Values presented in the graphs correspond to means ± standard error media
(SEM) of three independent set of samples blotted and quantified independently.
Proteomics data collection and iTRAQ quantitative analysis
Ventricle samples from 1-day-old neonate, 1-month, 3-month and 8-month-old mice were
analyzed. Two independent samples per age and genotype were pooled. Briefly, proteins were
digested using the filter aided sample preparation (FASP) protocol and the resulting peptides
labeled with iTRAQ, fractionated by cation exchange and analyzed by LC-MS/MS. Quantita-
tive data were analyzed using statistical models developed in our laboratory. Detailed descrip-
tion of the procedures and references can be found in S2 File.
Enzymatic caspase activity assay
Executioner caspase activity (Z-DEVD-AFC) was measured in neonatal cardiomyocytes, 293
cell extracts and heart samples as previously reported [16]. Protein concentration in the lysates
was measured by the Bradford assay (BioRad) and equal loads of protein were mixed with the
fluorogenic substrate (Calbiochem) at 50μM in 96-well plates. The plates were incubated at
37°C and fluorescence was read at intervals of 1h during the next 8h in the Infinite M200 fluo-
rimeter (Tecan), with excitation filter set at 360nm and emission filter set at 530nm.
Means ± SEM were calculated from three independent experiments performed in triplicates as
specified in the figure legend.
Statistical analysis
Student’s-t test was used for comparisons between wild type and knock out samples or scram-
bled/control and knockdown/overexpressing cell cultures, which involved experimental vari-
ables such as cell number, cell death, cell size, organ size, caspase enzymatic activity, mRNA
expression using RT-qPCR and protein abundance analyzed by Western Blot. Statistical analy-
sis details for the expression microarray and quantitative proteomics studies are specified in S2
File
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Results
Generation and initial characterization of the cardiac-specific caspase-3
deficient / caspase-7 deficient mouse: caspases influence myocyte
proliferation
Executioner caspase-3, -6 and -7 are expressed in the developing heart and are absent in the
terminally differentiated myocardium (Fig 1A) suggesting that they are relevant during heart
development. Progressive apoptotic gene silencing affects most of apoptotic genes and occurs
soon after birth [17, 24], coinciding with cardiomyocyte exit from cell cycle [25]. Within
Fig 1. Executioner caspases are expressed in the developing heart and their conditional deletion in the myocardium reducesmyocyte number at
birth. (A) Expression of caspases-3,-6 and -7 in total protein extracts of hearts of mice at different ages from embryonic day 16 (E16) to postnatal day 30
(P30). Alpha-actin is a marker of myocyte differentiation. Glyceraldehyde-phosphate dehydrogenase (GAPDH) is a loading control. (B) Subcellular
distribution of caspase-3 (Casp-3) and caspase-7 (Casp-7). Tot: total extract, Nuc: nucleus, Mit: mitochondria, Cyt: cytosol. DLD: dihydrolipoamide
dehydrogenase (mitochondrial marker); GAPDH (cytosolic marker); lamin (nuclear marker). (C) Heart weight of 3-day-old and 7-month-old wild type (WT)
and caspase-3 and caspase-7 knockout (KO) mice. N = 6 per age and genotype. (D) Cardiomyocyte number in hearts of male and female wild type (WT) and
double mutant (KO) mice. N = 5 per gender, age and genotype. (E) PCNA (Proliferating Cell Nuclear Antigen) immunostaining of heart tissue slices from
3-day-old wild type and double mutant mice and graph showing percent PCNA+ nuclei in cardiomyocytes (fibroblasts have small and compressed cytosol).
Bar: 20 µm. **, p<0.01 Student’s-t test KO vs. WT. Bars are means ± s.e.m.
doi:10.1371/journal.pone.0131411.g001
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cardiomyocytes, caspase-3 is expressed both in mitochondria and the cytosol, whereas caspase-
7 is mostly cytosolic (Fig 1B) despite in silico search for mitochondria targeting sequences
(MitoProt) [26] showed low probability of caspase-3 and -7 being exported to mitochondria
(coefficient: 0.02 and 0.01, respectively, compared to 0.76 for the mitochondrial apoptotic
nuclease EndoG).
Previous in vivo and in vitro studies suggest a role of executioner caspase-3 and -7 in heart
development and myocyte differentiation [8, 10]. On the contrary, caspase-6 knockout mice
have no overt cardiac alterations [27]. Although caspase-6 shares structural traits with caspase-
3 and -7, it diverges from these caspases in terms of target peptide requirements and substrate
affinity[1]. Whether caspase-3 and -7 are important in cardiomyocytes or abnormal cardiac
development ensues from caspase deficiency in other cells in vivo is unknown. To determine
the function of executioner caspases in the myocardium in vivo we designed a conditional
knockout mouse in which caspase-3 gene deletion depends on loxP recombination driven
by Cre recombinase expressed under the control of the Nkx2.5 basal promoter-cardiac
enhancer [14]. Nkx2.5 promoter directs gene expression from the onset of cardiac commitment
[14, 28]. Caspase-7 was deleted ubiquitously because the lack of phenotype observed previously
[8]. Caspase-3 and -7 double mutant mice were obtained by intercrossing caspase-3lox/lox,
caspase-7-/- and Nkx2.5::Cremice (Figure A in S3 File). Genotyping reaction (S2 File) was
designed to distinguish between caspase-3 floxed (e.g. tail, cardiac fibroblasts) and knockout
(myocardium) alleles. Western blot confirmed lack of caspase-7 expression in knockout mice
and remnant caspase-3 expression in the neonatal heart (Figure B in S3 File).
Caspase-3 and -7 double mutant mice were born at Mendelian frequency (4.9% vs. expected
4.7%, n = 184) (Figure A in S3 File) and reached adulthood normally. However, the hearts of
double knockout neonatal mice were 30% lighter than those of wild type mice, attaining nor-
mal weight by adulthood (Fig 1C). No differences were observed in heart anatomy between
genotypes (data not shown). Cell counting from formol-fixed hearts [22] showed reduced car-
diomyocyte number in double knockout mice at both ages, despite continued proliferation
after birth in both genotypes (Fig 1D). The postnatal proliferation results (compare cell num-
bers in Fig 1D left and right graphs) agree with recent findings showing a cardiomyocyte prolif-
erative burst in the postnatal heart [25], and also discard that normal heart weight of adult
caspase knockout mice was due to increased late myocyte proliferation in the knockouts. Pro-
liferating Cell Nuclear Antigen (PCNA) immunostaining of neonatal heart samples also agrees
with lower number of cardiomyocytes involved in DNA replication in caspase-3 and-7 double
knockout hearts (Fig 1E).
Lack of executioner caspases reduces transcription of genes involved in
DNA replication and cell cycle progression in the developing heart
To determine the molecular changes underlying reduced cardiomyocyte number in the absence
of executioner caspase expression, we performed a microarray-based gene expression analysis
comparing wild type and caspase-3 and -7 double knockout hearts in newborns, an age in
which wild type hearts still express caspases and in thirty-day-old mice, an age in which wild
type hearts have downregulated caspase signaling and myocytes do not further divide). Gene
functional categories most significantly affected in newborns by the lack of executioner cas-
pases were those regulating DNA replication and cell cycle, whereas in young mice the most
affected genes were those involved in tissue development (Fig 2A). Detailed inspection of tran-
scription changes showed that newborn caspase-deficient myocardium transcribed abnormally
low levels of genes coding for key proteins involved in DNA replication, recombination and
repair (e.g. pold1 coding for DNA polymerase subunit delta, topbp1 coding for DNA
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Fig 2. Executioner caspase deficiency in the developing myocardium triggers changes in gene expression in accordance to reducedmyocyte
proliferation. (A) Clustering of differentially expressed genes between wild type and caspase-3 and -7 double knockout mice by biological processes. Ploted
is the–log of P values adjusted by the Benjamini and Hochberg method. Highlighted is the process most significantly affected in newborns and young mice.
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topoisomerase-2 binding protein-1; BRCA1, PCNA, etc.), centromere and kinetochore forma-
tion (e.g. CENP genes, INCEMP, auroraB, etc.) and cell cycle regulation (e.g. cell division cycle-
6, ccne1 coding for cyclin-E), as well as some genes involved in metabolism (e.g. slc2a4 coding
for GLUT4, and hif3a, among others) (Fig 2B). In young hearts, lack of executioner caspases
during development resulted in abnormally high expression of genes involved in cell cycle inhi-
bition (such as fam107a, which was also increased in newborn knockouts), genes coding for
non-cardiac isoforms of sarcomeric proteins (myosin heavy chain-11 and tropomyosin-2), as
well as genes involved in embryonic development (hand2, gata5) and also resulted in slightly
reduced expression of genes coding for components of the contraction machinery (e.g. titin,
dystrophin, obscurin) (Fig 2B, Figure C in S3 File). Gene expression changes detected by the
microarray study were confirmed using specific quantitative PCR (qPCR) assays for a set of
key genes involved in the above mentioned functions (Fig 2C). Of note, the mRNA of natri-
uretic peptide A (nppa), which is a marker of myocyte hypertrophy [29], was highly expressed
in caspase-3 and -7 double mutant hearts and the opposite effect was observed for ndrg4,
which is involved in cardiomyocyte proliferation [30]. Western blotting analysis revealed that
changes in expression of selected proteins were coherent with the alterations observed in
mRNA abundance related to age and genotype (Fig 2D). The expression changes observed in
double mutant hearts were present yet modest in caspase-3 deficient hearts, while lack of cas-
pase-7 did not affect the expression of any gene checked (Figure D in S3 File). Gene expression
was also unaffected by Cre expression (Figure D in S3 File), discarding that changes observed
were due to expression of the recombinase used to interrupt caspase-3. Taken together, the
results obtained by the microarray-based gene expression study show that lack of caspase-3
and -7 in the developing myocardium deeply modifies the expression of genes involved in
DNA replication, recombination and repair, chromatin organization and cell cycle progression
in accordance with reduced cell proliferation. The results also show increased expression of
non-muscular and smooth muscle structural gene isoforms in hearts of young caspase knock-
outs, in accordance with the gene expression changes occurring during hypertrophy previously
described elsewhere [31].
Proteomic profiling suggests changes in energy metabolism in the
caspase-deficient heart
To gain further insight on the changes of protein abundance induced by executioner caspase
deficiency along developmental stages, we conducted a high-throughput quantitative proteo-
mics study. We used isobaric 8-plex peptide labeling (iTRAQ) followed by peptide prefractio-
nation before mass spectrometry analysis to make a simultaneous quantitation of the deep
cardiac proteome of wild type and executioner caspase knockout mice at four ages (1-day-old
and 1, 3 and 8-month-old animals). The quantitative data were then analyzed using the WSPP
model (S2 File), and were found to follow with good accuracy the predictions of the null
hypothesis at the spectrum, peptide and protein levels (Figure E in S3 File). Comparative
(B) Representation of top up-regulated genes (towards the red region of the bar) or down-regulated genes (towards the blue region of the bar) in newborn
and young knockout mice, colored by molecular function. (C) Reverse-transcription/qPCR was performed to validate the microarray results for the
expression of a set of genes downregulated (blue) or upregulated (red) in caspase KO hearts. N: newborn, Y: young. *, p<0.05, Student’s-t test KO vs. WT
for the same age. n = 5–7 cardiac RNA extracts per age and genotype. (D) Changes of protein abundance for a set of the differentially expressed genes
(selected by availability of antibodies with confirmed specificity). Upper panel: representative Western Blots (WB) featuring twoWT and two KO independent
cardiac protein extracts per age. Graphs: Densitometric analysis of WB. AU = Arbitrary units. *, p<0.05 KO vs. WT (Student’s-test) comparing the same age
(N: newborn, Y: young). N = 6 per age and genotype. Mef2a expression is used as a control of unaffected gene and GAPDH is used as loading control. Bars
are means ± s.e.m.
doi:10.1371/journal.pone.0131411.g002
Characterization of the Executioner Caspase-Deficient Mouse Heart
PLOS ONE | DOI:10.1371/journal.pone.0131411 June 29, 2015 9 / 21
analysis of the dynamic behavior of proteins along time (Fig 3A–3D) revealed a switch from
glycolytic to fatty acid oxidative metabolism through postnatal heart maturation [32] in both
genotypes. This was evident by the increase in abundance of enzymes from the β-oxidation
pathway (Fig 3A left and middle columns) and of components of oxidative phosphorylation
complexes (Fig 3B left and middle columns).Two populations of glycolytic enzymes were
defined in terms of their relative abundance along time (Fig 3C left and middle columns). On
the one hand, eleven proteins were downregulated along time (blue) compared to postnatal
expression (time 0, not shown). These proteins are coded by major glycolytic genes and their
abundance decreased with age. On the other hand, the abundance of six proteins increased
with age (red). From the later population, five proteins (ALDOA, a variant of ALDOA identi-
fied as A6ZI47,K6PF,PGAM and ENOB) correspond to muscle isoforms of glycolytic genes
enriched in the adult muscle, despite reduced glycolytic activity compared to the embryo [32].
Despite this trend was observed in both genotypes, the majority of oxidative phosphorylation
proteins were less abundant and glycolytic proteins were more abundant in the caspase-defi-
cient myocardium at birth and this difference attenuated along time (Fig 3B and 3C right col-
umns). We also observed that the abundance of the sarcomeric proteins troponin,
tropomyosin and tropomodulin was lower in the knockout hearts than in the wild type hearts
at birth, tending to reach similar levels in the adult (Fig 3D upper columns). On the contrary,
other sarcomeric proteins including dystrophin, titin, obscurin and the muscle-specific ryano-
dine receptors 1 and 2 were relatively more abundant in the knockout hearts at birth but did
not follow the normal developmental upregulation, resulting in abnormally low expression in
these hearts at adulthood (Fig 3D lower rows). Of note the non-muscle isoform ryanodine
receptor-3 (RYR3) was upregulated in the knockout hearts. To further illustrate the differences
due to genotype, the distribution of standardized log2-ratios (WT/KO) of proteins from these
categories was compared at 1 day and 8 months (Fig 3E). The sigmoid graphs show how
absence of executioner caspases in postnatal hearts, when wild type hearts still express caspases,
produced a protein distribution consistent with a more glycolytic and less oxidative metabo-
lism than wild type hearts, suggesting metabolic retardation. However, no differences become
appreciable at adulthood, suggesting adaptation towards an adult genotype, in which caspases
are normally absent in the myocardium (Fig 1A and references [17, 24]). Overall, these results
reveal that the caspase-deficient myocardium suffers changes in metabolic enzymes and pro-
teins involved in contraction suggesting a relative retardation and alteration of cardiomyocyte
maturation.
Cardiomyocyte hypertrophy occurs in the heart deficient for caspase-3
and -7
The increased expression of non-muscular and smooth muscle isoforms of structural genes
observed by transcriptomics, and the trend towards glycolytic embryonic-like metabolism
detected by proteomics in young adult knockout’s hearts were suggestive of hypertrophy. This
molecular signature was associated with postnatal recovery of knockout heart’s weight in the
absence of increased cardiomyocyte proliferation. Therefore, we measured cardiomyocyte
cross-sectional area in cardiac slices of neonatal, young and adult wild type and double knock-
out mice by wheat germ agglutinin (WGA) staining, which labels extracellular matrix, as previ-
ously described [20]. Cardiomyocyte mean cross-sectional area was unaffected in neonatal
hearts (Fig 4A, upper graph), but septal myocyte cross-sectional area increased by 30% in cas-
pase-3 and-7 double knockout hearts by 3 months (Fig 4A, middle graph), and both septal and
ventricular myocytes were larger in mutant hearts at 7 months (Fig 4A, lower graph and right
panels). Adaptive changes in myocyte size were associated with normal heart function in adult
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knockout mice (Fig 4B). We next assessed whether adaptive growth of caspase-deficient myo-
cytes was due to changes in the susceptibility of myocytes to hypertrophic stimuli. Infusion of
the β-adrenergic agonist isoproterenol induced identical response in wild type and caspase
knockout hearts (Fig 4C), and discarded hypersensitivity of mutant hearts to hypertrophic sti-
muli. The above results show that cardiomyocyte hypertrophy is a gradual response of the
hypoplastic caspase-deficient heart expanding beyond the period of caspase expression in wild
type hearts.
Expression of genes involved in the control of cell proliferation in
developing myocytes is regulated by executioner caspases
independently of their catalytic activity
To investigate how executioner caspases regulate the expression of the genes found altered by
transcriptomics and proteomics in the cardiac-specific executioner caspase knockout’s heart,
we overexpressed wild type caspase-3 and -7 or caspase mutants bearing a Cysteine to Serine
substitution in the catalytic site in P4-5 rat postnatal myocytes (Fig 5A and 5B), which express
low levels of apoptotic genes [24], and we assessed the expression of genes affected by in vivo
caspase deletion. Rat neonatal cardiac myocytes were chose instead of mouse myocytes due to
the difficulty in obtaining healthy and abundant cultures of the later and based on the validity
of inter-species comparisons reported elsewhere [33]. Wild type and mutant caspases were
overexpressed at similar levels (Fig 5C). Caspase proteolytic activity was altered neither in car-
diomyocytes overexpressing caspase-3 and -7 nor in hearts deficient for these caspases (Fig
5D). Increased caspase activity was detected only when the kinase inhibitor staurosporine, an
inducer of apoptosis [17], was added to the culture medium of the HEK293 cell line or wild
type caspase-overexpressing myocytes (Fig 5D). Lack of caspase activity in normal, non-over-
expressing, postnatal myocytes is due to very low expression of these genes, as previously
described [24].This experiment also confirmed that Cysteine to Serine mutation abolishes cas-
pase proteolytic activity (Fig 5D). Overexpression of wild type zymogens or the inactive
mutants lead to similar increases in the expression of genes downregulated in the caspase
knockout myocardium, confirming a direct implication of caspases in the control of genes
involved in the regulation of myocyte proliferation (Fig 5E). We further confirmed enhanced
expression at the protein level for cyclin-E (Fig 5F), which is involved in the proliferation of
terminally differentiated myocytes [34]. Caspase overexpression also induced a small yet signif-
icant downregulation of serpina3 expression (Fig 5E), a gene upregulated in the caspase knock-
out hearts, confirming that caspase overexpression induced opposite effects than those
observed in caspase-deficient myocytes. Furthermore, observation that changes in gene
Fig 3. Quantitative proteomics analysis indicates metabolic changes due to executioner caspase
deficiency in accordance with reducedmyocyte maturation. (A-D)Relative abundance profiles of
selected proteins along development (0, 1, 3 and 8-month-old) in both wild type (WT) and caspase-3 and -7
knockout (KO) animals; in the left and middle columns, the changes are expressed separately for KO andWT
animals in relation to the abundances at t = 0, while in the rightmost column the abundance of proteins in the
KO are compared with that of theWT animals at each time point. Selected proteins include those belonging
to beta-oxidation (A), oxidative phosphorylation complexes, whose identification can be found in Figure G in
S3 File. (B), glycolysis (C) and structural and contractile proteins (D); in the case of glycolysis, for simplicity
only the main or housekeeping isoforms are depicted. Red squares indicate increased abundance vs.
neonatal values in columns referred to age (left and middle), and increased abundance vs. WT in columns
comparing genotypes (right), while blue squares indicate decrease in relative protein abundance. The
distribution of standardized log2-ratios (KO/WT) of proteins belonging to oxidative phosphorylation
complexes and glycolysis in neonates (red lines) and in adults (blue lines) and the null hypothesis distribution
(black lines) are compared in (E), where a trend to the left denotes increased abundance and a trend to the
right indicates lower abundance vs. the null hypothesis.
doi:10.1371/journal.pone.0131411.g003
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Fig 4. Executioner caspase-deficiency induces progressive cardiomyocyte hypertrophy without affecting heart function. (A) Progressive increase
of cardiomyocyte (CM) cross-sectional area in the septum and ventricular wall of wild type (WT) and caspase-3 and -7 double knockout (KO) mice. **,
p<0.01 KO vs. WT. N = 6 per gender, age and genotype. Representative microscopy images of heart histological preparations stained with FITC-WGA of
7-months-old WT and KOmice, bar: 50µm. (B) Cardiac function of 3-month-old wild type (WT) and caspase-3 and -7 double knockout (KO) mice. BW, body
weight; IVS, inter-ventricular septum thickness; LVPW, left ventricular posterior wall thickness; LVEDD, left ventricular end diastolic diameter; LVESD, left
ventricular end systolic diameter; EF, ejection fraction; FS, left ventricular fractional shortening; HR, heart rate in beats per minute. N = 9 (WT) and 10 (KO).
P, statistical analysis by Student’s-t test. (C) Beta-adrenergic agonist-induced cardiac hypertrophy in wild type (WT) and caspase-3 and -7 double knockout
(KO) mice (N = 6/genotype). Isoproterenol (ISO) at 8.8mg/kg/day or saline vehicle was administered to five 20-week-old mice per genotype using
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expression in the caspase-deficient hearts and in cardiomyocytes overexpressing either wild
type or mutant caspases occur in the absence of changes in caspase activity demonstrate that
gene expression regulation by executioner caspases is independent of caspase proteolytic
activity.
Discussion
The results of this study show that executioner caspase-3 and -7 are required during heart
development to attain the correct number of myocytes in mice. Transcriptomic results show
that caspase-3 and -7 are required for the normal expression of a broad set of genes involved in
DNA replication, recombination, repair and chromatin organization as well as genes regulating
cell cycle progression. Quantitative proteomics shows that executioner caspases foster the cor-
rect transition from glycolytic to oxidative metabolism in differentiating cardiomyocytes.
Within the frame of the natural silencing of caspase genes during perinatal cardiac develop-
ment, the above results suggest that the expression of caspases during heart development and
their progressive silencing during the first weeks after birth contribute to the transition from a
proliferative to a differentiated post-mitotic myocardium. In addition, we show that caspases
do not require their proteolytic activity for regulating gene expression in myocytes.
Involvement of caspases in cardiomyocyte division during heart development, shown here,
justify the broad expression of caspases in the myocardium during cardiac tissue growth by cell
proliferation and the repression of these genes afterwards, as previously described by our group
[17, 24] and others [35]. The findings presented here also improve the understanding of the
involvement of executioner caspases in heart development. Previous in vivo studies of mice
mutant for caspase-3, -7 or -8, or its positive (FADD) and negative (cFLIP) regulators, sug-
gested the impact of caspase deficiency in heart trabeculation and ventricular wall compaction
without affecting cell death [5–8]. Also, in vitro experiments using caspase inhibitors in cul-
tured rodent cardiac or skeletal myocytes, P19 teratocarcinoma-derived cell line and mouse
embryos showed a role of caspase activity in myocyte differentiation [10, 36]. However, pheno-
type rescuing by ex vivo culture of caspase-8 knockout embryo suggested that cardiac defects
ensued secondary to placental problems in these mice, not directly to lack of caspase activity in
the myocardium [11]. In addition, there are some discrepancies in the results obtained by phar-
macological inhibition of caspase activity between studies performed with chicken embryos [9]
and ex-vivo cultured mouse embryos [10]. In chicken embryos, caspase inhibitors hampered
correct outflow tract looping and insertion of aortic and pulmonary arteries in the heart [9],
while treatment of E12.5 mouse embryos with caspase inhibitors had no impact on the forma-
tion of these structures [10] despite the ongoing construction of the arterial connections at this
period of mouse embryo development [37]. Here, we show that the most evident phenotype of
the Nkx2.5::Cre-driven conditional caspase-3 null / caspase-7 null mouse is reduced cardio-
myocyte number and this effect seems independent to proteolytic activity since no caspase-like
activity was detected in the myocardium and the effects on gene expression of caspase overex-
pression in neonatal myocytes occurred also in the absence of increased caspase activation.
Therefore, in vivo results suggest that cardiac phenotypes previously described of mice with
ubiquitous caspase deletion and changes in chicken embryos and ex-vivo cultured mouse
embryos treated with caspase inhibitors could probably be due to inhibition of other enzymes
or blockade of caspase activity in other cells or embryo tissues, not related to caspase function
subcutaneously implanted osmotic pumps. Seven days later, heart weight and tibia length were recorded. *, p<0.05 Student’s-t test ISO vs. saline for each
genotype. NS = not statistically significant changes. Bars are means ± s.e.m.
doi:10.1371/journal.pone.0131411.g004
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Fig 5. Overexpression of caspase-3 and -7 in postnatal cardiomyocytes induces increased expression of genes regulating cell division,
independently of caspase proteolytic activity. (A) Electropherogram fragments of human Caspase-3 and Caspase-7 overexpression vectors showing the
induced G!Cmutation of the catalytic site’s Cystein codon that generates a Serine codon (MutC-S). (B) Scheme of an executioner caspase showing the
Cystein to Serine substitution in the p17 domain (*). N, NH4
+-terminal end; C, carboxyl end. Pro: prodomain. (C)Overexpression efficiency of wild type (C3/7)
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specifically in cardiomyocytes. Alternatively, embryos with cardiac-specific deletion of caspases
could activate cardiac adaptive responses to circumvent limited differentiation but cannot
completely recover cardiomyocyte number.
Inhibition of Wnt/β-catenin signaling contributes to heart formation [38], while Wnt sig-
naling allows cardiomyocyte expansion [39, 40]. Wnt11 promotes cardiac differentiation [41]
and a peak of caspase-3/7-like activity induced by Wnt11 was described to be required for P19
carcinoma cell line differentiation to myocytes (e.g. expression of troponin T _tnt_) at least in
part through β-catenin degradation [10]. This was in agreement with progressive reduction of
Wnt activity in the developing mouse myocardium. In addition, Wnt signaling was blunted in
the heart by caspase inhibitors in ex-vivo cultured E12.5 and E14.5 embryos resulting in
reduced number of α-myosine heavy chain-positive (MHC+) cardiomyocytes detected by
immunofluoerscence [10]. However, we did not detect changes in MHC expression by in vivo
deletion of executioner caspase-3 and -7 in cardiomyocytes in neonatal hearts. Lack of change
in MHC expression despite reduced cardiomyocyte number can be explained probably because
most of the myocardial protein comes from myocytes and therefore, reduced myocyte number
does not affect relative structural protein abundance (i.e. fibroblast’s protein contributes mini-
mally to the total protein of the myocardium). To gain further insight into the potential rela-
tionship between caspases andWnt signaling in our model, we assessed β-catenin expression
in protein extracts of neonatal and young hearts from wild type and caspase-deficient mice and
of rat neonatal cardiomyocytes overexpressing caspase-3 and 7. Although β-catenin expression
was reduced with age, we show that it was modified by executioner caspase abundance neither
in vivo nor in vitro (Figure F in S3 File). These results could refine previous reports suggesting
that caspase-3 target β-catenin and showing that other proteases could be involved in β-catenin
processing [10].
The prevalence of glycolysis in neonatal caspase deficient hearts, as indicated by the prote-
ome analysis of newborn samples, suggests an initial retardation of the switch from glycolytic
to oxidative metabolism occurring through normal heart maturation [32]. Growing evidence
indicates that metabolic status influences or is influenced by proliferation [42]. In fact, reduced
mitochondrial activity blocks proliferation without compromising cell growth in hepatocytes
[43] and cyclinB1/cdk1-induced phosphorylation of mitochondrial proteins improves mito-
chondrial respiration, facilitating cell proliferation [44]. Our results show that caspase-3 is
expressed in mitochondria and cytosol, in agreement with previous reports [45], whereas cas-
pase-7 is mostly cytosolic. They also show that caspase-3 compensates for caspase-7 deficiency
in the regulation of gene expression, but the reverse is only partial. Together, these findings
suggest a relevant function of caspase-3 in mitochondria that could be involved in the control
of genes regulating cell division. Based in the above facts, we speculate that a reduction in the
expression of the machinery for mitochondrial oxidative metabolism induced by caspase defi-
ciency in cardiomyocytes could compromise proliferation but not growth.
and mutant (C3/7mut) caspases in P4-5 postnatal rat cardiomyocytes. Ctl: control with empty vector showing caspase endogenous expression. Image is
representative of 3 independent experiments. (D) DEVDase (executioner caspase-like) enzymatic activity detected in extracts from rat neonatal
cardiomyocytes overexpressing wild type (Casp.) or mutant (Casp.Mut.) executioner caspase-3 and 7 or empty vector (;) and cultured in the absence (Ctl,
control) or presence of 1 µM staurosporine (S) during 24 hours, or from neonatal wild type (WT) and caspase-3 and -7 double knockout (KO) mice’s hearts.
HEK293 cell line was used as positive control of staurosporine-triggered caspase activity. *, p<0.05 and ns: not significant for comparison of staurosporine-
induced caspase activity between cardiomyocytes overexpressing caspases or empty vector, Student’s-t test. N = 3. (E)Relative mRNA expression for
different proteins whose expression is modified in caspase-3 and -7 knockout hearts was assessed in total RNA extracts from cultured P4-5 postnatal rat
cardiomyocytes overexpressing wild type caspases (C3&C7), mutant caspases (C3mut&C7mut) or empty vector (control). *, p<0.05 caspase-
overexpressing vs. control cultures, Student’s-t test, n = 6. (F) Assessment of cyclin-E expression in cardiomyocyte cultures transduced with empty (Control)
or caspase-3 and -7 overexpressing vectors (Overexp.), representative blot and graph showing densitometric analysis, *, p<0.05 vs. control, n = 5.
doi:10.1371/journal.pone.0131411.g005
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A limitation of our study is intrinsic to the in vivo approach, which is, in turn, one of its
stronger points respect previous works. Live models developed in their natural environment
have a powerful capacity to adapt for surviving and hence, vital functions of the targeted genes
can be carried out through alternative pathways, softening the phenotype. This is the case of
the E2F1-null and E2F1/E2F2 compound-mutant mice, which develop and reproduce nor-
mally [24, 46, 47] yet show abnormal T lymphocyte maturation and pancreatic dysfunction
respectively, despite the relevant role of E2F1 and E2F2 in many cellular functions including
cell division [48]. Therefore, cardiac-specific caspase-3 null / caspase-7 null mouse’s hypoplas-
tic phenotype could ensue from lack of their most irreplaceable function during heart develop-
ment. Previous studies of chicken embryos and ex vivo cultured mouse embryos treated with
caspase inhibitors found altered cardiac formation and lack of myocyte differentiation as mea-
sured by sarcomeric protein expression that could be due to drugs targeting other cells or tis-
sues or even other enzymes [9, 10]. Nevertheless, our study cannot discard a role of caspases in
the signaling for cardiomyocyte structural differentiation, which could be accomplished by
alternative pathways in the cardiomyocyte-specific executioner caspase-deficient mouse.
Finally, our results suggest that the function of caspase-3 and -7 in developing cardiomyo-
cytes is independent of their proteolytic activity. Prodomain-mediated signaling could account
for proteolytic-independent functions of caspases with long prodomain such as caspase-2 and
-8 [49], but the short prodomain of executioner caspases challenge the validity of this hypothe-
sis for the cardiac function of caspase-3 and -7 reported here. However, catalytic-independent
role of caspase-3 in fibronectin secretion by fibroblasts has been recently reported [50]. Thus,
although we do not provide a molecular mechanism by which caspases regulate gene expres-
sion, our results suggest that non-proteolytic activity of executioner caspases is more common
than assumed.
Transcriptomic comparison of wild type and executioner caspase-deficient hearts at differ-
ent developmental time points underscored the influence of executioner caspases on the
expression of genes regulating different aspects of cell division, such as DNA replication, chro-
mosome segregation and cell cycle progression. Quantitative proteomics allowing simulta-
neous comparison of four time-points identified changes in metabolic pathways showing
reduced abundance of proteins involved in oxidative phosphorylation and increased glycolytic
protein abundance in neonatal knockout hearts compared to wild types, which was progres-
sively normalized during postnatal development. Thus, combining transcriptomics, which
were later confirmed by protein electrophoresis and Western Blot, and proteomics contributed
information on complementary molecular signaling altered by the lack of executioner caspases
during heart development. The report of non-canonical role of executioner caspases in the reg-
ulation of cell proliferation, maturation and growth, irrespective of their proteolytic activity
and through the regulation of gene expression to influence heart development, opens an excit-
ing field of biomedical research that could contribute clues to understand and eventually treat
cardiac congenital diseases.
Conclusions
The work presented here shows that: 1) Executioner caspase-3 and 7 are expressed in the devel-
oping rodent heart and are progressively silenced after birth. 2) Subcellular distribution of
these caspases differs: caspase-3 is expressed in mitochondria and cytosol and caspase-7 is
mostly cytosolic. 3) Lack of caspase-3 in cardiomyocytes accompanied by ubiquitous deletion
of caspase-7 during mouse development reduces the final number of cardiomyocytes. 4) The
hypoplastic neonatal heart of caspase-3 and 7 double null mouse express abnormally low levels
of genes regulating DNA replication/repair and cell cycle and express abnormally high levels of
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non-myocyte sarcomeric genes that usually are repressed during differentiation. 5) The proteo-
mic profile of the neonatal caspase-deficient myocardium shows abnormally high abundance
of glycolytic enzymes and lower abundance of proteins involved in oxidative phosphorylation
compared to wild type hearts. 6) These changes in gene expression in vivo are not correlated
with changes in caspase-like activity and proteolytically inactive caspases overexpressed in neo-
natal myocytes can affect the expression of some genes regulating cell division with identical
efficiency than wild type caspases.
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